Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor? - Wikidata - awgldk - TriplyDB

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

http://www.wikidata.org/entity/Q35892429

about

Breast cancer molecular subtypes: from TNBC to QNBC Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.

P2860

Q28076805-BFF21EE2-857C-4CD5-BE37-F1B9637FC09B Q37580136-99B61FD7-5916-4065-905C-7EDA8EEBBFBF Q55170957-6648F15E-7C9D-4B76-A2E2-F28BE4F6B1DC

P2860

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

http://www.wikidata.org/entity/Q35892429

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@ast

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@en

type

label

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@ast

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@en

prefLabel

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@ast

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@en

P1433

Q35892429-FBC644C1-8295-4AEB-A075-A53511C18B9D

P1476

Q35892429-76C73CF2-8216-4F06-A134-C92FD8CC9A80

P2093

Q35892429-0CDFCA44-B5AA-42C4-B8B7-8EBF51DD180C

Q35892429-2DA7A394-3D80-4612-9196-184BC0A87FD8

Q35892429-5927C149-6D97-4CB7-8725-C9443339940B

Q35892429-6DF0CBEA-6551-4D83-AEC1-35582E15FF2C

Q35892429-6F27BBBB-DCF3-4921-85F4-4976D60436DE

Q35892429-75A4D765-1ECC-4BFB-89E9-23106ED9C2E4

Q35892429-76BC0B4D-FE5A-4C07-98E7-EE9D9F1502AC

Q35892429-7B272B8A-5375-458C-A1C4-085D118B57F5

Q35892429-7FE29A59-D899-4ACD-B9A7-B1D630B17C80

Q35892429-8CCC5E73-FCFE-41C3-8A7D-F0C2FAD1917E

P2860

Q35892429-02F373D9-5AC3-4D6E-8FF6-FEBE99073D83

Q35892429-2003E7C9-4D72-41A8-A8C8-83AD6D592BA9

Q35892429-2A4214E0-6635-4C2D-83AF-FA667BBD540A

Q35892429-302A1C0F-F02B-49A1-8023-562B2B10DFB9

Q35892429-4A789ECC-97DF-4791-B887-CF58317E1302

Q35892429-5EA26034-2655-45F6-9009-52315D9672EF

Q35892429-61F3E828-4DAE-41D2-A621-5D7A295453C6

Q35892429-84CC80D9-DD45-41C8-98AD-3746C503E32A

Q35892429-8EC09B91-0C75-4C1F-92AE-BE50466102EE

Q35892429-9C0E79EB-6001-4F6B-8378-D6B22D6671D3

P304

Q35892429-BFA1F244-181D-4893-9231-E9888C1DB339

P31

Q35892429-E35E995C-7990-41C5-9593-5BB5D041DBBC

P356

Q35892429-468A7295-C6B6-4BDA-8CAF-984AA119D040

P407

Q35892429-4EBC55EF-31B9-4C4E-A92B-EAD67B443A53

P478

Q35892429-34145B6F-8926-495B-80BD-CDE1846D97CF

P50

Q35892429-4E514749-4C86-46AB-B5AB-DBE84C7F0A94

P577

Q35892429-4B05ED80-A37E-4991-A8ED-9A082F732006

P5875

Q35892429-D4787F21-6E22-46AD-B5E0-F40BE059F6E8

P698

Q35892429-22D9412E-1E98-49A4-8D26-0CC7DF701BC2

P932

Q35892429-60ADDBEC-3B81-4763-BA31-2AA8B6D0ADBF

P356

P1433

OncoTargets and Therapy

P1476

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

@en

P2093

Alexandra Tsigginou

http://www.w3.org/2001/XMLSchema#string

Alexandros Rodolakis

http://www.w3.org/2001/XMLSchema#string

Anita Brandstetter

http://www.w3.org/2001/XMLSchema#string

Aris Antsaklis

http://www.w3.org/2001/XMLSchema#string

Aris Giannos

http://www.w3.org/2001/XMLSchema#string

Constantine Dimitrakakis

http://www.w3.org/2001/XMLSchema#string

Flora Zagouri

http://www.w3.org/2001/XMLSchema#string

Irene Papaspyrou

http://www.w3.org/2001/XMLSchema#string

Maria Sotiropoulou

http://www.w3.org/2001/XMLSchema#string

Martin Filipits

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

Role of the androgen receptor in human breast cancer.

Androgen receptor expression and breast cancer survival in postmenopausal women.

Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.

Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation

The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

Prognostic markers in triple-negative breast cancer.

P304

1843-1847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S78254

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

P577

2015-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281817870

http://www.w3.org/2001/XMLSchema#string

P698

26229492

http://www.w3.org/2001/XMLSchema#string

P932

4516182

http://www.w3.org/2001/XMLSchema#string